TESARO (NASDAQ:TSRO)‘s stock had its “buy” rating reissued by stock analysts at Citigroup in a research report issued to clients and investors on Wednesday, Marketbeat reports. They currently have a $135.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $216.00. Citigroup’s price target would indicate a potential upside of 76.77% from the company’s current price.

A number of other research firms have also commented on TSRO. Robert W. Baird reissued a “neutral” rating and issued a $125.00 price target on shares of TESARO in a research report on Monday, October 2nd. Cann reissued a “buy” rating and issued a $199.00 price target on shares of TESARO in a research report on Friday, September 8th. BidaskClub raised TESARO from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 23rd. Oppenheimer reissued a “buy” rating and issued a $199.00 price target on shares of TESARO in a research report on Sunday, September 10th. Finally, Zacks Investment Research lowered TESARO from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $156.01.

TESARO (NASDAQ:TSRO) traded down $0.53 during midday trading on Wednesday, reaching $76.37. The company had a trading volume of 554,251 shares, compared to its average volume of 1,011,445. TESARO has a twelve month low of $76.19 and a twelve month high of $192.94. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34.

TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.69. The business had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. TESARO’s quarterly revenue was up 740.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.72) EPS. equities analysts expect that TESARO will post -8.18 EPS for the current year.

In other news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $85.24, for a total transaction of $70,663.96. Following the completion of the transaction, the senior vice president now owns 8,101 shares in the company, valued at approximately $690,529.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Martin H. Jr. Huber sold 592 shares of the stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $118.60, for a total value of $70,211.20. Following the transaction, the senior vice president now owns 6,943 shares of the company’s stock, valued at approximately $823,439.80. The disclosure for this sale can be found here. 34.60% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. AXA grew its stake in shares of TESARO by 89.3% during the 3rd quarter. AXA now owns 121,449 shares of the biopharmaceutical company’s stock worth $15,679,000 after acquiring an additional 57,300 shares during the period. Iguana Healthcare Management LLC grew its stake in shares of TESARO by 66.7% during the 3rd quarter. Iguana Healthcare Management LLC now owns 25,000 shares of the biopharmaceutical company’s stock worth $3,228,000 after acquiring an additional 10,000 shares during the period. Neuberger Berman Group LLC grew its stake in shares of TESARO by 22.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 153,540 shares of the biopharmaceutical company’s stock worth $19,822,000 after acquiring an additional 28,500 shares during the period. Bamco Inc. NY grew its stake in shares of TESARO by 30.7% during the 3rd quarter. Bamco Inc. NY now owns 13,128 shares of the biopharmaceutical company’s stock worth $1,695,000 after acquiring an additional 3,087 shares during the period. Finally, Perceptive Advisors LLC grew its stake in shares of TESARO by 8.1% during the 3rd quarter. Perceptive Advisors LLC now owns 388,651 shares of the biopharmaceutical company’s stock worth $50,175,000 after acquiring an additional 29,100 shares during the period.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/20/tesaro-tsro-earns-buy-rating-from-citigroup.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.